Ken Fisher Crinetics Pharmaceuticals, Inc. Transaction History

Fisher Asset Management, LLC

$213 Billion
Q1 2024

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 436,023 shares of CRNX stock, worth $19.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

436,023

Previous 441,295 1.19%

Holding current value

$19.4 Million

Previous $15.7 Million 29.99%

% of portfolio

0.01%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$34.76 - $46.81 $183,254 - $246,782	-5,272 Reduced 1.19%	436,023 $20.4 Million
Q4 2023 Mar 05, 2024	BUY	$25.62 - $37.07 $10,299 - $14,902	402 Added 0.09%	441,295 $15.7 Million
Q4 2023 Feb 06, 2024	BUY	$25.62 - $37.07 $9.92 Million - $14.3 Million	387,033 Added 718.59%	440,893 $15.7 Million
Q3 2023 Nov 13, 2023	SELL	$15.97 - $30.59 $230,143 - $440,832	-14,411 Reduced 21.11%	53,860 $1.6 Million
Q2 2023 Dec 12, 2023	BUY	$15.73 - $23.6 $226,685 - $340,099	14,411 Added 26.76%	68,271 $1.23 Million

Q2 2023 Aug 08, 2023	SELL	$15.73 - $23.6 $136,111 - $204,210	-8,653 Reduced 11.25%	68,271 $1.23 Million
Q1 2023 Dec 12, 2023	BUY	$15.31 - $21.1 $220,632 - $304,072	14,411 Added 26.76%	68,271 $1.1 Million
Q4 2022 Feb 03, 2023	BUY	$15.49 - $19.05 $365,068 - $448,970	23,568 Added 44.17%	76,924 $1.41 Million
Q3 2022 Nov 08, 2022	BUY	$18.11 - $22.37 $966,277 - $1.19 Million	53,356 New	53,356 $1.05 Million

Others Institutions Holding CRNX

# of Institutions

220

Shares Held

75.8M

Call Options Held

631K

Put Options Held

749K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.39B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account